With all due respect I am starting to believe that

With all due respect I am starting to believe that Lympro's true advantage is time and that it will be first to market. As far as 3 to 5 years from now I sure hope Lympro has been sold for a good return. Being the first to market plus the amount of savings this would bring to big pharm in AD studies is as plain as day. Considering this diagnostic is literally weeks away from revenue with no cash up front partner or attractive buyout offers is mind boggling to me. Common sense tells me there must be something I am missing. I feel like big pharm should be opening their check books almost with the same urgency I am buying shares at these levels. IMHO I believe big pharm is thinking yeah we will use Lympro save money for the next several years, however as far as writing that 500 million dollar check for an AD diagnostic its gonna be when we believe the true gold standard is ready for market in a few years. They have a better understanding of what is being developed out there than I do. I believe that Lympro will bring revenue and value to Amarantus however Im not sure its the long term gold standard AD diagnostic. Just fund MANF and ELTO....however hope im wrong.